Fig. 1

NAP1L1 expression in hepatocellular carcinoma tissues. a IHC assays of NAP1L1 expression in adjacent non-tumor tissues and tumor (left ×200, scale bar: 100 μm). NAP1L1 expression levels in tumor tissue are significantly higher than those in adjacent non-tumor tissue (n = 20). The IHC H-scores are shown as mean with SD (right). b Representative staining of negative NAP1L1 expression in the tumor cell cytoplasm (left ×40, right ×200; scale bar: 100 μm). c Representative staining of positive NAP1L1 expression in the tumor cell cytoplasm (left ×40, right ×200). d Kaplan–Meier analysis for OS displayed as the NAP1L1-lo group versus the NAP1L1-Hi group in present study (left). TCGA data (https://www.proteinatlas.org/) further confirmed that high NAP1L1 expression indicated reduced OS of HCC patients (right). e Kaplan–Meier analysis for DFS displayed as the NAP1L1-lo group versus the NAP1L1-Hi group in present study. f Kaplan–Meier analysis for recurred patients who treated with TACE as the NAP1L1-lo group versus the NAP1L1-Hi group. IHC Immunohistochemistry, SD standard deviation, OS overall survival, TCGA The Cancer Genome Atlas, DFS disease-free survival, TACE transarterial chemoembolization. *p < 0.05